Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
| ▸ | POLG | P54098 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352459 | 1.00 | POLB (0.58) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL13169192 | 1.00 | POLB (0.58) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL4450475 | 0.91 | POLB (0.48) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL4450483 | 0.91 | POLB (0.48) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1763156 | 0.91 | POLB (0.61) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL16790089 | 0.90 | POLB (0.47) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL16790092 | 0.89 | POLB (0.47) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL12721603 | 0.89 | POLB (0.46) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3684936 | 0.89 | LMNA (0.48) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL29711392 | 0.89 | POLB (0.46) | POLBP2RY2P2RY4P2RY6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7928086-B2 | Administering a beta -L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug therapy of a host infected with a drug-resistant form of HBV that exhibits a mutation at the 552 codon from methionine to valine in the DNA polymerase region | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7928086-B2 | Administering a beta -L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug therapy of a host infected with a drug-resistant form of HBV that exhibits a mutation at the 552 codon from methionine to valine in the DNA polymerase region | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | POLB 66/4885P2RY2 606/4885P2RY4 1578/4885 |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | SLC28A2, SLC28A1, SLC29A2 | POLB 71/4885P2RY2 800/4885P2RY4 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.